Literature DB >> 20513553

Lyme disease.

Thomas S Murray1, Eugene D Shapiro.   

Abstract

Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States. The clinical presentation varies depending on the stage of the illness: early disease includes erthyma migrans, early disseminated disease includes multiple erythema migrans, meningitis, cranial nerve palsies, and carditis; late disease is primarily arthritis. The symptoms and signs of infection resolve in most patients after treatment with appropriate antimicrobials for 2 to 4 weeks. Serologic testing should be used judiciously as it often results in misdiagnosis when performed on blood from patients with a low prior probability of disease and those with only nonspecific symptoms such as fatigue or arthralgia without objective signs of infection. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20513553      PMCID: PMC3652387          DOI: 10.1016/j.cll.2010.01.003

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  62 in total

1.  Doxycycline for tick bites--not for everyone.

Authors:  E D Shapiro
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

Review 2.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

3.  The presenting manifestations of Lyme disease and the outcomes of treatment.

Authors:  Allen C Steere; Vijay K Sikand
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

4.  Lyme disease--United States, 2001-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-05-07       Impact factor: 17.586

5.  Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi.

Authors:  R Mark Wooten; Ying Ma; R Alyson Yoder; Jeanette P Brown; John H Weis; James F Zachary; Carsten J Kirschning; Janis J Weis
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

6.  Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease.

Authors:  M S Klempner; L T Hu; J Evans; C H Schmid; G M Johnson; R P Trevino; D Norton; L Levy; D Wall; J McCall; M Kosinski; A Weinstein
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

7.  Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite.

Authors:  R B Nadelman; J Nowakowski; D Fish; R C Falco; K Freeman; D McKenna; P Welch; R Marcus; M E Agüero-Rosenfeld; D T Dennis; G P Wormser
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

8.  Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease.

Authors:  R A Kalish; G McHugh; J Granquist; B Shea; R Ruthazer; A C Steere
Journal:  Clin Infect Dis       Date:  2001-08-10       Impact factor: 9.079

9.  Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans.

Authors:  R R Müllegger; G McHugh; R Ruthazer; B Binder; H Kerl; A C Steere
Journal:  J Invest Dermatol       Date:  2000-12       Impact factor: 8.551

10.  Bacteriolytic activity of selected vertebrate sera for Borrelia burgdorferi sensu stricto and Borrelia bissettii.

Authors:  Amy J Ullmann; Robert S Lane; Klaus Kurtenbach; Michael Miller; Martin E Schriefer; Nordin Zeldner; Joseph Piesman
Journal:  J Parasitol       Date:  2003-12       Impact factor: 1.276

View more
  32 in total

1.  Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010.

Authors:  Shahram Shahangian; Todd D Alspach; J Rex Astles; Ajay Yesupriya; William K Dettwyler
Journal:  Arch Pathol Lab Med       Date:  2013-06-05       Impact factor: 5.534

2.  Longistatin in tick saliva blocks advanced glycation end-product receptor activation.

Authors:  Takeshi Hatta; Takeharu Miyoshi; Makoto Matsubayashi; M Khyrul Islam; M Abdul Alim; M Abu Anas; M Mehedi Hasan; Yasunobu Matsumoto; Yasuhiko Yamamoto; Hiroshi Yamamoto; Kozo Fujisaki; Naotoshi Tsuji
Journal:  J Clin Invest       Date:  2014-10       Impact factor: 14.808

3.  Bacterial heterogeneity is a requirement for host superinfection by the Lyme disease spirochete.

Authors:  Artem S Rogovskyy; Troy Bankhead
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

4.  Increasing Burden of Lyme Carditis in United States Children's Hospitals.

Authors:  Cheyenne M Beach; Stephen A Hart; Andrew Nowalk; Brian Feingold; Kristen Kurland; Gaurav Arora
Journal:  Pediatr Cardiol       Date:  2019-11-14       Impact factor: 1.655

5.  Peripheral facial palsy as an initial symptom of Lyme neuroborreliosis in an Austrian endemic area.

Authors:  Wolfgang Kindler; Hubert Wolf; Katrin Thier; Stefan Oberndorfer
Journal:  Wien Klin Wochenschr       Date:  2015-01-10       Impact factor: 1.704

6.  Lyme Carditis: A Case Report and Review of Management.

Authors:  Sheheryar Muhammad; Robert J Simonelli
Journal:  Hosp Pharm       Date:  2018-01-02

7.  Longistatin, a plasminogen activator, is key to the availability of blood-meals for ixodid ticks.

Authors:  M Khyrul Islam; M Abdul Alim; Takeharu Miyoshi; Takeshi Hatta; Kayoko Yamaji; Yasunobu Matsumoto; Kozo Fujisaki; Naotoshi Tsuji
Journal:  PLoS Pathog       Date:  2011-03-10       Impact factor: 6.823

8.  Detecting Lyme disease using antibody-functionalized single-walled carbon nanotube transistors.

Authors:  Mitchell B Lerner; Jennifer Dailey; Brett R Goldsmith; Dustin Brisson; A T Charlie Johnson
Journal:  Biosens Bioelectron       Date:  2013-02-04       Impact factor: 10.618

9.  Pancytopenia in Lyme disease.

Authors:  Raman Mehrzad; Joseph Bravoco
Journal:  BMJ Case Rep       Date:  2014-03-04

10.  Enhanced detection of host response antibodies to Borrelia burgdorferi using immuno-PCR.

Authors:  Micah D Halpern; Sunny Jain; Mollie W Jewett
Journal:  Clin Vaccine Immunol       Date:  2013-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.